{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:28:44Z","timestamp":1777328924414,"version":"3.51.4"},"reference-count":14,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,6,21]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Carfilzomib is a selective proteosome inhibitor that is commonly used in the treatment of relapsed or refractory multiple myeloma. Carfilzomib has been commonly associated with respiratory side effects. It can rarely also cause fatal pulmonary toxicity. We present a case of a man in his 50s with plasma cell leukaemia who was initiated on treatment with carfilzomib and dexamethasone. He developed severe pneumonitis requiring oxygen via a high-flow nasal cannula. After an extensive workup, a temporal relationship between the carfilzomib use and exacerbation of the pulmonary symptoms was found. Carfilzomib was permanently discontinued, and the patient was started promptly on methyl prednisolone with complete resolution of his symptoms. Due to the associated risk of mortality if not detected early, we wish to highlight this rare but serious pulmonary toxicity associated with carfilzomib that was managed with high-dose glucocorticoids.<\/jats:p>","DOI":"10.1136\/bcr-2022-251173","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:11:39Z","timestamp":1656936699000},"page":"e251173","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Severe pulmonary toxicity related to carfilzomib use: a rare but serious side effect"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-3322","authenticated-orcid":false,"given":"Arthi","family":"Sridhar","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas McGovern Medical School, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0207-329X","authenticated-orcid":false,"given":"Binoy","family":"Yohannan","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, The University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johncy John","family":"Kachira","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameeksha","family":"Bhama","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, The University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"2025082712263187000_15.7.e251173.1","first-page":"303","article-title":"Carfilzomib (Kyprolis): a novel proteasome inhibitor for relapsed and\/or refractory multiple myeloma","volume":"41","author":"Perel","year":"2016","journal-title":"P T"},{"key":"2025082712263187000_15.7.e251173.2","first-page":"87","article-title":"Incidence and management of adverse events in patients with relapsed and\/or refractory multiple myeloma receiving single-agent carfilzomib","volume":"6","author":"Harvey","year":"2014","journal-title":"Clin Pharmacol"},{"key":"2025082712263187000_15.7.e251173.3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.32601","article-title":"Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database","volume":"126","author":"Fakhri","year":"2020","journal-title":"Cancer"},{"key":"2025082712263187000_15.7.e251173.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.08.003"},{"key":"2025082712263187000_15.7.e251173.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414359"},{"key":"2025082712263187000_15.7.e251173.6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.29"},{"key":"2025082712263187000_15.7.e251173.7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089334"},{"key":"2025082712263187000_15.7.e251173.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"2025082712263187000_15.7.e251173.9","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215588630"},{"key":"2025082712263187000_15.7.e251173.10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.52964\/AMJA.0880","article-title":"Fatal pulmonary toxicity following carfilzomib administration","volume":"20","author":"Marschall","year":"2021","journal-title":"Acute Med"},{"key":"2025082712263187000_15.7.e251173.11","unstructured":"Desai D , Keer N , Geva T . Carfilzomib-related severe pneumonitis. Lung Transpl Drug Induced Lung Disease Case Rep 2018."},{"key":"2025082712263187000_15.7.e251173.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2016.08.506","article-title":"Carfilzomib pulmonary toxicity","volume":"150","author":"Bhagavath","year":"2016","journal-title":"Chest"},{"key":"2025082712263187000_15.7.e251173.13","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.healun.2021.01.2052","article-title":"Carfilzomib-induced pneumotoxicity in a lung transplant recipient","volume":"40","author":"Razia","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2025082712263187000_15.7.e251173.14","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600988010"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-251173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:26:39Z","timestamp":1756322799000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-251173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":14,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,4]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bcr-2022-251173"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-251173","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}